Neuromod Devices Ltd intensified its global commercial push for Lenire, its bimodal neuromodulation tinnitus therapy, with a strong presence at key audiology conferences in the U.S. and Australia this week. The company is using these professional forums to spotlight clinical data, workflow integration, and market need in tinnitus care.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
At the American Academy of Audiology 2026 meeting in San Antonio, Neuromod is sponsoring multiple sessions focused on future tinnitus treatment models. Presentations cover bimodal neuromodulation, biometric tracking, and real-world Lenire outcomes, including internal data citing clinically significant relief in 82% of patients.
Speakers such as business development manager Cheri Hebeisen and audiologist Dr. Laura Bradley Pratesi are positioned to explain patient selection, clinical workflows, and emerging standards of care. This educational focus aims to embed Lenire within mainstream audiology and ENT practice rather than as a niche adjunct therapy.
In parallel, Neuromod highlighted Lenire at the ACAud 2026 event in Gold Coast, Australia, where representatives engaged clinicians from Booth 31. The company underscored Medical Journal of Australia data showing 33% of Australians have experienced tinnitus and 17% report constant noise, emphasizing a large national addressable market.
Across Australian communications, Lenire is described as a home-based, non-invasive solution supported by three large-scale clinical trials and real-world patient data. By combining prevalence statistics with evidence-based positioning, Neuromod is targeting both clinician confidence and patient convenience to drive adoption.
Strategically, the week’s activity points to an execution focus on clinician-channel development, conference visibility, and evidence-led differentiation. If Neuromod can convert heightened professional awareness in the U.S. and Australia into routine clinical use, these initiatives may support broader market penetration and reinforce its standing in neuromodulation-based tinnitus therapy.